This article looks at the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy.
The S&P 500 rose by 0.52% on Friday to close at a record high of 6,173.07, marking returns of 3.44% for the week, as traders looked past the termination of trade talks between the United States and Canada. The broad market index rallied during the week after the White House spokesperson downplayed the looming July tariff deadlines, hinting that these could be delayed by President Trump.
The stock market has gained nearly 24% since hitting its lows in April, culminating in a remarkable turnaround that has overcome a series of economic and geopolitical challenges. Strong earnings, a stable labor market, and the revival of AI trade have also contributed to the rebound.
Jamie Cox, managing partner at Harris Financial Group, shared the following remarks on the rally:
“The markets are looking forward, seeing lower interest rates, less regulation in the banking sector, a shift from austerity to stimulus in Europe, and a less biting inflation and tariff environment. This sure isn’t the stagflation story we’ve been told to brace for.”
However, Louis Miller, a senior Goldman Sachs Group trader, has warned investors to approach the recent surge with caution. This is especially true for lower-quality parts of the market, where short sellers are under pressure to cover their positions.
“We flagged two weeks ago that the short squeeze the market was facing could provide an opportunity to press shorts lower, and we think that time is getting closer.”
With that said, let’s now head over to discuss the top large-cap stocks in the Goldman Sachs portfolio.
A high-rise city building with a computer-generated chart reflecting the stock market index on its glass façade.
Methodology
For this article, we scanned Goldman Sachs’ 13F portfolio as of Q1 2025. From there, we picked the top 10 large-cap stocks and ranked them in ascending order of their stake value.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy:
10. Eli Lilly and Company (NYSE:LLY)
Stake Value: $4,404,820,511
Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. On June 25, the company announced that the FDA had approved a label update for Amyvid to support the diagnosis of Alzheimer’s disease.
The florbetapir F 18 injection is used for brain imaging of patients with cognitive impairment who are being tested for Alzheimer’s. Eli Lilly and Company (NYSE:LLY) said the new label changes will include revised guidelines to estimate plaque density and provide a new indication for patient selection.
The updated label will also allow the quantification of amyloid plaque levels in conjunction with visual understanding. Moreover, the clinical studies section of the label will acknowledge that amyloid beta positron emission tomography (PET) scans had aided in assessing plaque reduction in some trials of amyloid-targeting therapies.
Mark Mintun, M.D., group vice president, Neuroscience Research & Development, at Eli Lilly and Company (NYSE:LLY), stated the following on the development:
“Nearly 80% of Americans would prefer to know if they have an Alzheimer’s diagnosis before their memory and thinking symptoms disrupt daily life, highlighting the importance of advanced diagnostic tools like amyloid PET and blood biomarker testing. The modernization of Amyvid’s label is a significant step in advancing Alzheimer’s care, enabling physicians to help patients make informed decisions, being evaluated for or to aid in the selection of patients who are indicated for amyloid-targeting therapy.”
Eli Lilly and Company (NYSE:LLY) is a medicine company that has pioneered life-changing discoveries for the last 150 years, helping tens of millions of patients across the globe.
9. Broadcom Inc. (NASDAQ:AVGO)
Stake Value: $4,632,873,960
Broadcom Inc. (NASDAQ:AVGO) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. The stock has had impressive returns over the past month, gaining 14.30% during the period, as of June 27.
On June 5, the company reported second-quarter earnings that beat Wall Street expectations. Broadcom Inc. (NASDAQ:AVGO) also provided robust guidance for the third quarter, betting on strong demand for its chips. It has forecast a revenue of $15.80 billion for Q3, above the analysts’ average estimate of $15.71 billion and 21% higher year-over-year.
Following the earnings call, several firms lifted the outlook for Broadcom Inc. (NASDAQ:AVGO), which has also strengthened investor sentiment. This included Benchmark, which raised the stock’s price target to $315 from $255 while maintaining a Buy rating for the company’s shares. Barclays has also hiked the stock’s price target to $265 from $215 and reiterated the earlier Overweight rating.
Broadcom Inc. (NASDAQ:AVGO) recently announced the general availability of VMware Cloud Foundation (VCF) 9.0, a platform for contemporary private cloud environments, which is set to accelerate innovation, control cloud costs, and enhance data control to enable security and sovereignty.
Broadcom Inc. (NASDAQ:AVGO) is a global technology company specializing in the design, development, and distribution of semiconductors, enterprise software, and security solutions.